Diagnosis and Treatment of Invasive Mold Diseases

키워드

참고문헌 (67)

1. Drgona L, "Clinical and economic burden of invasive fungal diseases in Europe : focus on pre-emptive and empirical treatment of Aspergillus and Candida species", Eur J Clin Microbiol Infect Dis, 33, pp.7~21 (2014)
2. Webb BJ, "Epidemiology and clinical features of invasive fungal infection in a US health care network", Open Forum Infect Dis, 5, pp.ofy187~ (2018)
3. Yoon HJ, "Prevalence of fungal infections using National Health Insurance data from 2009-2013, South Korea", Epidemiol Health, 36, pp.e2014017~ (2014)
4. Kim SH, "Fatal scedosporiosis in multiple solid organ allografts transmitted from a nearly-drowned donor", Am J Transplant, 15, pp.833~840 (2015)
5. Choi Hyeah, "Bloodstream Infections in Patients with Hematologic Diseases: Causative Organisms and Factors Associated with Resistance", Infection and Chemotherapy, 54(2), pp.340~352 (2022), 대한감염학회[DOI]
6. Chang CL, "Acute cerebral phaeohyphomycosis due to Wangiella dermatitidis accompanied by cerebrospinal fluid eosinophilia", J Clin Microbiol, 38, pp.1965~1966 (2000)
7. Azie N, "The PATH(Prospective antifungal therapy)Alliance® registry and invasive fungal infections : update 2012", Diagn Microbiol Infect Dis, 73, pp.293~300 (2012)
8. Eren Esma, "The Outcome of Fungal Pneumonia with Hematological Cancer", Infection and Chemotherapy, 52(4), pp.530~538 (2020), 대한감염학회[DOI]
9. Bae Moonsuk, "Infections in Lung Transplant Recipients during and after Prophylaxis", Infection and Chemotherapy, 52(4), pp.600~610 (2020), 대한감염학회[DOI]
10. Ascioglu S, "Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants : an international consensus", Clin Infect Dis, 34, pp.7~14 (2002)
11. Chai LY, "Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis", PLoS One, 9, pp.e90176~ (2014)
12. Maertens JA, "Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi(SECURE) : a phase 3, randomisedcontrolled, non-inferiority trial", Lancet, 387, pp.760~769 (2016)
13. Maertens JA, "Posaconazole versus voriconazole for primary treatment of invasive aspergillosis : a phase 3, randomised, controlled, non-inferiority trial", Lancet, 397, pp.499~509 (2021)
14. Marr KA, "Combination antifungal therapy for invasive aspergillosis : a randomized trial", Ann Intern Med, 162, pp.81~89 (2015)
15. 김성한, "침습성 폐 아스페르길루스증의 역학과 임상상: 전국 다기관 연구", Infection and Chemotherapy, 44(4), pp.282~288 (2012), 대한감염학회
16. De Pauw B, "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer", Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group(EORTC, Clin Infect Dis, pp.2008, 46[DOI]
17. Donnelly JP, "Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium", Clin Infect Dis, 71, pp.1367~1376 (2020)
18. Caillot D, "Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia", J Clin Oncol, 19, pp.253~259 (2001)
19. Greene R, "The radiological spectrum of pulmonary aspergillosis", Med Mycol, 43(Suppl 1), pp.S147~54 (2005)
20. Logan PM, "High-resolution computed tomography and pathologic findings in pulmonary aspergillosis : a pictorial essay", Can Assoc Radiol J, 47, pp.444~452 (1996)
21. Logan PM, "Invasive aspergillosis of the airways : radiographic, CT, and pathologic findings", Radiology, 193, pp.383~388 (1994)
22. Park SY, "Computed tomography findings in invasive pulmonary aspergillosis in non-neutropenic transplant recipients and neutropenic patients, and their prognostic value", J Infect, 63, pp.447~456 (2011)
23. Lim C, "Analysis of initial and follow-up CT findings in patients with invasive pulmonary aspergillosis after solid organ transplantation", Clin Radiol, 67, pp.1179~1186 (2012)
24. Jung J, "Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis", Clin Microbiol Infect, 21, pp.684~ (2015)
25. Wahba H, "Reversed halo sign in invasive pulmonary fungal infections", Clin Infect Dis, 46, pp.1733~1737 (2008)
26. Francis P, "Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits : the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection", J Infect Dis, 169, pp.356~368 (1994)
27. Patterson JE, "Hospital epidemiologic surveillance for invasive aspergillosis : patient demographics and the utility of antigen detection", Infect Control Hosp Epidemiol, 18, pp.104~108 (1997)
28. Verweij PE, "Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections", Med Mycol, 36(Suppl 1), pp.146~155 (1998)
29. Maertens JA, "Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay", Clin Infect Dis, 44, pp.1329~1336 (2007)
30. Mercier T, "Defining galactomannan positivity in the updated EORTC", MSGERC consensus definitions of invasive fungal diseases, 2021, pp.72(Suppl 2), S89~94
31. Karageorgopoulos DE, "β-D-glucan assay for the diagnosis of invasive fungal infections : a meta-analysis", Clin Infect Dis, 52, pp.750~770 (2011)
32. Pini P, "Evaluation of serum(1 → 3)-β-D-glucan clinical performance : kinetic assessment, comparison with galactomannan and evaluation of confounding factors", Infection, 44, pp.223~233 (2016)
33. Arvanitis M, "PCR in diagnosis of invasive aspergillosis : a meta-analysis of diagnostic performance", J Clin Microbiol, 52, pp.3731~3742 (2014)
34. White PL, "Aspergillus polymerase chain reaction-an update on technical recommendations, clinical applications, and justification for inclusion in the second revision of the EORTC", MSGERC definitions of invasive fungal disease, 2021, pp.72(Suppl 2), S95~101
35. Bae S, "Invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome", Clin Infect Dis, 70, pp.1491~1494 (2020)
36. Schauwvlieghe AFAD, "Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza : a retrospective cohort study", Lancet Respir Med, 6, pp.782~792 (2018)
37. Xu Y, "Invasive pulmonary aspergillosis is a frequent complication in patients with severe fever with thrombocytopenia syndrome : A retrospective study", Int J Infect Dis, 105, pp.646~652 (2021)
38. Blot SI, "A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients", Am J Respir Crit Care Med, 186, pp.56~64 (2012)
39. Verweij PE, "Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition : an expert opinion", Intensive Care Med, 46, pp.1524~1535 (2020)
40. Raeseok Lee, "Risk factors and clinical impact of COVID-19- associated pulmonary aspergillosis: multicenter retrospective cohort study", The Korean Journal of Internal Medicine, 37(4), pp.851~863 (2022), 대한내과학회[DOI]
41. Salmanton-García J, "COVID-19-associated pulmonary aspergillosis, March-August 2020", Emerg Infect Dis, 27, pp.1077~1086 (2021)
42. Chong WH, "Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis(CAPA) : a systematic review", J Hosp Infect, 113, pp.115~129 (2021)
43. Husain S, "Invasive aspergillosis in solid-organ transplant recipients : guidelines from the American Society of Transplantation Infectious Diseases community of practice", Clin Transplant, 33, pp.e13544~ (2019)
44. Patterson TF, "Practice guidelines for the diagnosis and management of aspergillosis : 2016 update by the Infectious Diseases Society of America", Clin Infect Dis, 63, pp.e1~60 (2016)
45. Ullmann AJ, "Diagnosis and management of Aspergillus diseases : executive summary of the 2017 ESCMID-ECMM-ERS guideline", Clin Microbiol Infect, 24(Suppl 1), pp.e1~38 (2018)
46. Stevens DA, "Practice guidelines for diseases caused by Aspergillus", Clin Infect Dis, 30, pp.696~709 (2000)
47. Herbrecht R, "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N Engl J Med, 347, pp.408~415 (2002)
48. Park WB, "The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections : a randomized controlled trial", Clin Infect Dis, 55, pp.1080~1087 (2012)
49. Jenks JD, "Broad spectrum triazoles for invasive mould infections in adults: Which drug and when?", Med Mycol, 57(Supplement_2), pp.S168~S178 (2019)
50. Cornely OA, "Liposomal amphotericin B as initial therapy for invasive mold infection : a randomized trial comparing a high-loading dose regimen with standard dosing(AmBiLoad trial)", Clin Infect Dis, 44, pp.1289~1297 (2007)
51. Maertens J, "Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy", Clin Infect Dis, 39, pp.1563~1571 (2004)
52. Denning DW, "Micafungin(FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis", J Infect, 53, pp.337~349 (2006)
53. Cleary JD, "Echinocandins : pharmacokinetic and therapeutic issues", Curr Med Res Opin, 25, pp.1741~1750 (2009)
54. Cuenca-Estrella M, "Combinations of antifungal agents in therapy--what value are they?", J Antimicrob Chemother, 54, pp.854~869 (2004)
55. Yoon Young Kyung, "Guidelines on Implementing Antimicrobial Stewardship Programs in Korea", Infection and Chemotherapy, 53(3), pp.617~659 (2021), 대한감염학회[DOI]
56. Cornely OA, "Global guideline for the diagnosis and management of mucormycosis : an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium", Lancet Infect Dis, 19, pp.e405~21 (2019)
57. 홍효림, "Risk Factors for Mortality in Patients with Invasive Mucormycosis", Infection and Chemotherapy, 45(3), pp.292~298 (2013), 대한감염학회
58. Chamilos G, "Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis", Clin Infect Dis, 47, pp.503~509 (2008)
59. Marty FM, "Isavuconazole treatment for mucormycosis : a single-arm open-label trial and case-control analysis", Lancet Infect Dis, 16, pp.828~837 (2016)
60. Greenberg RN, "Posaconazole as salvage therapy for zygomycosis", Antimicrob Agents Chemother, 50, pp.126~133 (2006)
61. van Burik JA, "Posaconazole is effective as salvage therapy in zygomycosis : a retrospective summary of 91 cases", Clin Infect Dis, 42, pp.e61~5 (2006)
62. "Clin Chest Med", 2009, 337~353
63. Tortorano AM, "ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis : Fusarium spp., Scedosporium spp. and others", Clin Microbiol Infect, 20(Suppl 3), pp.27~46 (2014)
64. Sampathkumar P, "Fusarium infection after solid-organ transplantation", Clin Infect Dis, 32, pp.1237~1240 (2001)
65. Ramirez-Garcia A, "Scedosporium and Lomentospora : an updated overview of underrated opportunists", Med Mycol, 56(suppl_1), pp.102~125 (2018)
66. Chowdhary A, "ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis : diseases caused by black fungi", Clin Microbiol Infect, 20(Suppl 3), pp.47~75 (2014)
67. McCarty TP, "Phaeohyphomycosis in transplant recipients : Results from the transplant associated infection surveillance network(TRANSNET)", Med Mycol, 53, pp.440~446 (2015)

관련 논문AI추천